As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
BUSINESS
Astellas, Harvard Conduct Joint Research for Retinitis Pigmentosa
Astellas Pharma has entered into a research collaboration agreement with an investigator at Harvard Medical School to discover the pathologic mechanism of retinitis pigmentosa, identify new therapeutic targets, and to provide a new treatment option to retinitis pigmentosa patients, the…
To read the full story
BUSINESS
- Eisai to Unify Global HR Framework by 2029 to Bolster Leqembi Growth
November 25, 2025
- Marubeni Pharma Targets Doubling Profits by FY2035 with 2 New Deals Each Year
November 25, 2025
- Sanofi Seeks Age 60+ Access as Japan Plans NIP Addition of Efluelda for 75+
November 25, 2025
- Kyowa Kirin Begins Japan PIII Trial of Infigratinib for Achondroplasia
November 25, 2025
- Expert Expects New 21-Valent Pneumococcal Shot Capvaxive to Curb Invasive Disease
November 25, 2025
Japan is set to tighten reimbursement rules for regenerative medicine products granted conditional, time-limited approval, with Central Social Insurance Medical…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…